<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147368</url>
  </required_header>
  <id_info>
    <org_study_id>arginine</org_study_id>
    <secondary_id>GR071614MA - Wellcome Trust</secondary_id>
    <nct_id>NCT00147368</nct_id>
  </id_info>
  <brief_title>Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria</brief_title>
  <official_title>Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menzies School of Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MSHR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Health Research and Development (NIHRD), Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rumah Sakit Mitra Masyarakat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menzies School of Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide
      (NO) production. Both are associated with poor outcome. This study will examine the safety
      and effect of escalating doses of arginine in falciparum malaria. It will determine whether
      arginine can increase NO production and have an effect on NO-dependent physiological
      measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will
      return plasma arginine concentration to normal/supranormal levels; will increase systemic and
      exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological
      measures of relevance to malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exhaled and systemic nitric oxide production</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic (PK) parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic (PD) parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidant stress</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gas transfer</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial activation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a priori subgroup analysis: endothelial function in those with baseline impairment of function</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malaria, Falciparum</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous (IV) arginine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 18-60 years

          2. P. falciparum parasitemia (1,000-100,000 parasites/ul).

          3. Clinical syndrome consistent with malaria associated with documented fever (axillary
             temperature &gt; 38℃) or self-reported history of fever in the last 48 hours with no
             other cause present

          4. Commenced oral quinine ≤ 18 hours prior to scheduled commencement of arginine

          5. An indication for hospital admission (eg relative cannot look after/supervise
             treatment at home but not having any warning signs or severe malaria criteria in
             &quot;exclusion criteria&quot; below)

          6. Informed consent obtained

        Exclusion Criteria:

          1. Pregnancy or lactation

          2. Mixed infection with P. falciparum and P. vivax

          3. Warning signs of altered mental state and inability to sit unaided

          4. Features of severe/complicated malaria

          5. Diabetes

          6. Systolic blood pressure (BP) &lt; 100 mmHg

          7. Serious underlying disease (cardiac, hepatic, kidney)

          8. Initial iSTAT test showing any of the following values:

               -  glucose &lt; 4 mmol/L;

               -  K+ ≥ 4.2 meq/L;

               -  Cl- &gt; 106 meq/L;

               -  HCO3- &lt; 20 meq/L.

          9. Known allergy to L-arginine

         10. Concurrent therapy with any of the following medications:

               -  spironolactone;

               -  oral nitrates;

               -  phosphodiesterase inhibitor (eg sildenafil [Viagra]);

               -  alpha-blocking antihypertensive agents (eg prazosin);

               -  L-arginine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick M Anstey, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSHR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RSMM Hospital</name>
      <address>
        <city>Timika</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, Darcy CJ, Granger DL, Weinberg JB, Lopansri BK, Price RN, Duffull SB, Celermajer DS, Anstey NM. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med. 2007 Oct 29;204(11):2693-704. Epub 2007 Oct 22.</citation>
    <PMID>17954570</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>May 30, 2008</last_update_submitted>
  <last_update_submitted_qc>May 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Nicholas Anstey</name_title>
    <organization>Menzies School of Health Research</organization>
  </responsible_party>
  <keyword>falciparum</keyword>
  <keyword>malaria</keyword>
  <keyword>arginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

